GF Fund Management’s Ascendis Pharma A/S ASND Stock Holding History

GF Fund Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348K	Sell	1,305 -74	-5%	-$17.3K	﹤0.01%	233
2026 Q1	$315K	Buy	1,379 +173	+14%	+$38.8K	0.01%	248
2025 Q4	$257K	Sell	1,206 -103	-8%	-$21.3K	﹤0.01%	270
2025 Q3	$260K	Sell	1,309 -235	-15%	-$43.8K	﹤0.01%	267
2025 Q2	$266K	Hold	1,544	–	–	0.01%	299
2025 Q1	$241K	Buy	1,544 +278	+22%	+$39.7K	0.01%	308
2024 Q4	$174K	Buy	+1,266	New	+$166K	﹤0.01%	301

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

GF Fund Management's ASND Position: Q2 2026 in Review

GF Fund Management reduced its Ascendis Pharma A/S (ASND) stake by 5.4% in Q2 2026, selling an estimated $17.3K and leaving 1,305 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #233.

GF Fund Management first reported a position in ASND in Q4 2024 and has held it in 7 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

GF Fund Management held 1,305 shares of Ascendis Pharma A/S worth $348K as of Q2 2026.
GF Fund Management sold 74 Ascendis Pharma A/S shares in Q2 2026, an estimated $17.3K.
Ascendis Pharma A/S made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #233 holding.
GF Fund Management first reported a position in Ascendis Pharma A/S in Q4 2024 and has held it in 7 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.